nad has been researched along with Parkinson Disease, Secondary in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, YL; Hou, YF; Huang, GR; Li, ST; Liu, JM; Shan, C; Sun, LH; Tao, B; Wang, SM; Zhao, HY; Zhu, Q; Zhuang, QQ | 1 |
| Cooney, A; Goldstein, DS; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 1 |
| Burkhardt, K; Kaftan, A; Schwarz, J; Storch, A | 1 |
| Dabbeni-Sala, F; Franceschini, D; Giusti, P; Skaper, SD | 1 |
| Frei, B; Richter, C | 1 |
| Castagnoli, N; Ramsay, RR; Singer, TP; Trevor, AJ | 1 |
6 other study(ies) available for nad and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Protective effects of β- nicotinamide adenine dinucleotide against motor deficits and dopaminergic neuronal damage in a mouse model of Parkinson's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Humans; Male; Mice; Microinjections; Mitochondria; Motor Activity; NAD; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary | 2019 |
Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Dopamine; Electron Transport Complex I; Glioblastoma; Glioma; Humans; NAD; Parkinson Disease, Secondary; PC12 Cells; Rats; Rotenone; Uncoupling Agents | 2015 |
1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Dopamine; Dose-Response Relationship, Drug; Electron Transport Complex I; Electron Transport Complex II; Energy Metabolism; Glucose; Herbicides; Humans; Isoquinolines; Mitochondria; Multienzyme Complexes; NAD; NADH, NADPH Oxidoreductases; Neuroblastoma; Oxidoreductases; Parkinson Disease, Secondary; Rotenone; Succinate Dehydrogenase; Tumor Cells, Cultured; Uncoupling Agents | 2000 |
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
Topics: Adenosine Triphosphatases; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Electron Transport Complex IV; Electrophoresis, Polyacrylamide Gel; Male; Melatonin; Mitochondria; Motor Activity; NAD; Neuroprotective Agents; Oxidative Phosphorylation; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |
N-methyl-4-phenylpyridine (MMP+) together with 6-hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Calcium; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Dopamine; Egtazic Acid; Female; Hydroxydopamines; In Vitro Techniques; Mitochondria; NAD; Oxidopamine; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats; Rats, Inbred Strains | 1986 |
Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformation; Brain; Humans; Mitochondria; Monoamine Oxidase; NAD; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats | 1987 |